AZN craters 9% as drug trial flops pre-market

🌅 Today's Morning Call

S&P Futures 7,544.25 ▲ +5.25 (+0.07%)	Nasdaq Futures 29,703.25 ▲ +197.50 (+0.67%)	Dow Futures 52,588.00 ▼ -103.00 (-0.20%)
10Y Treasury 4.57% ▲ +0.04%	US Dollar 100.98 ▲ +0.00 (+0.00%)	Bitcoin $62,680 ▲ +$442 (+0.71%)

Good morning! Thursday, July 9th is serving up a mixed bag before the opening bell, with tech futures nudging higher while the Dow lags and pharma takes a gut punch. The big story this morning is AstraZeneca, which is sliding hard after a closely watched heart drug trial came back empty-handed. Markets haven't opened yet, but the pre-market tape is already telling a story. Here's your morning rundown.

👀 What to Watch Today

Today's session will be shaped largely by how investors digest a wave of company-specific news rather than any single macro catalyst. Treasury yields continue to creep higher, with the 10-year sitting at 4.57% and the 30-year touching 5.07%, which keeps pressure on rate-sensitive sectors heading into the open. Watch whether that yield drift starts weighing on the broader tape as the day progresses.

Volkswagen's stakeholder meeting is one of the more consequential corporate events on the calendar today. The automaker's plan to slash tens of thousands of jobs and shutter factories is meeting significant internal resistance, and how that meeting resolves could set the tone for European industrial stocks. VWAGY is worth tracking closely if you have any exposure to legacy auto.

On the macro side, keep an eye on the dollar index holding near 101 and Bitcoin nudging above $62,600. Neither is making dramatic moves, but both are useful barometers for risk sentiment as the session gets underway. Any meaningful shift in crypto or the DXY could signal a broader repositioning.

Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This [ad]

🌏 Overnight Recap

Overnight, European markets were absorbing a pair of notable corporate developments. SAP got a reprieve from EU antitrust regulators, who accepted the software giant's offer to make it easier for customers to switch providers or exit contracts. That concession was enough for regulators to close the investigation without a fine, which is a meaningful win for Europe's largest software maker and clears a significant legal overhang.

Also grabbing attention across the Atlantic was the NATO summit aftermath. The alliance wrapped up its Ankara gathering having navigated another round of friction with President Trump, but European members are signaling they expect more turbulence ahead in the relationship. The geopolitical backdrop remains unsettled, which tends to keep defense-adjacent names in focus.

In the auto sector, Porsche reported a 16% drop in first-half deliveries, citing the end of production for the gasoline-powered 718, tough year-over-year comparisons from strong electric Macan demand, and the expiration of U.S. tax incentives. POAHY is worth watching at the open for any sympathy moves into related EV or luxury auto names.

He doesn't buy gold. He just profits from it. [ad]

📊 Pre-Market Movers

AZN is the headline mover this morning, dropping roughly 9% in pre-market trading after the company and partner Ionis revealed that Wainua missed its primary endpoint in a late-stage cardiovascular trial. The drug was supposed to reduce deaths and recurring heart problems, and that it came up short is a significant setback for AstraZeneca's pipeline ambitions. IONS is also likely to feel the heat at the open as the co-developer of the drug.

On the brighter side, SAP is a name to watch for potential upside after EU regulators accepted its competition remedies and closed the antitrust probe without imposing a fine. That kind of regulatory resolution tends to be a quiet positive catalyst that gets repriced into the stock over the course of the session rather than all at once.

Nasdaq futures are outperforming this morning, up 0.67%, suggesting the tech complex is finding some early morning buyers even as the Dow futures dip slightly into the red. The divergence between tech and industrials is a theme worth tracking as the day unfolds.

I’m shouting ‘Buy Now’ before this stock soars [ad]

🔍 Today's Watchlist

1. AZN: Watch for continued selling pressure after the 9% pre-market drop on the Wainua trial failure
2. IONS: Ionis Pharmaceuticals also in focus as co-developer of the failed AstraZeneca heart drug
3. VWAGY: Volkswagen stakeholder meeting today on major restructuring plan involving factory closures and job cuts
4. 10-Year Treasury at 4.57%: Rising yields could cap gains in rate-sensitive growth and real estate names
5. SAP: EU antitrust resolution removes a legal overhang, potential positive catalyst heading into today's session

🎯 The Morning Playbook

The playbook for today starts with staying disciplined around the AZN and IONS selloff. Clinical trial failures can create sharp overreactions in both directions, and while a 9% drop is painful, the question for opportunistic investors is whether the broader AstraZeneca pipeline still holds value beyond one missed endpoint. That's a research question worth sitting with before touching the stock.

Beyond pharma, the Volkswagen meeting and Porsche delivery miss are reminders that legacy auto is still fighting through a messy transition. VWAGY and POAHY are not for the faint of heart right now, but the restructuring story at VW could eventually create a leaner, more investable company on the other side.

The broader market setup is genuinely mixed this morning, and that is not necessarily a bad thing. Mixed markets reward stock pickers more than momentum chasers. Do the work on the individual names, respect where rates are sitting, and let the tape come to you today.

2:59 PM Friday. Make this trade. [ad]